Protocol Ledger

NCT07176312 · Phase II · RECRUITING

Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

Interventional Phase II clinical trial protocol NCT07176312 sponsored by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-16 Enrollment: 80 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07176312
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)80 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07176312
Protocol FieldVerified Registry Value
NCT IdentifierNCT07176312
Consolidated Lead SponsorInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment80 participants (ESTIMATED)
Registered Start Date2026-01-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07176312
Hospital Research SiteLocationSite Profile
Universitätsklinikum Hamburg-EppendorfHamburg, GermanyOpen Hospital Dossier ->
Universitätsklinikum JenaJena, GermanyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI